Logo

Moderna Reports Positive Interim P-I Data of mRNA-1273 Against COVID-19

Share this

Moderna Reports Positive Interim P-I Data of mRNA-1273 Against COVID-19

Shots:

  • Immunogenicity data are available for the 25µg & 100µg dose level (aged 18-55yrs.) after two doses (day 43) and at the 25µg level after one dose (day 29). All the participants are seroconverted by day15 following a single dose- @43day 2wks. following the second dose- at the 25µg- levels of binding Abs were at the levels seen in convalescent sera while at 100µg-  levels of binding Abs exceeded the levels seen in convalescent sera
  • Neutralizing Ab data are available only for the first four participants in each of the 25µg & 100µg dose level cohorts. mRNA-1273 vaccination elicited neutralizing Abs in all eight of participants- as measured by PRNT assays. mRNA-1273 was safe and well-tolerated
  • Following interim P-I data- P-II study will be amended to study two dose levels- 50 & 100 µg- with the aim of selecting a dose for pivotal studies. The anticipated dose for P-III study to be b/w 25µg & 100 µg- expected to be initiated in July

Click here ­to­ read full press release/ article | Ref: Moderna | Image: Moderna

Related News: Moderna’s mRNA-1273 Receives the US FDA’s Fast Track Designation to Treat COVID-19


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions